Urotensin II (human)

• CAT Number: P000097
• CAS Number: 251293-28-4
• Molecular Formula: C64H85N13O18S2
• Molecular Weight: 1388.577
• Purity: ≥95%
• Target: Urotensin-II Receptor
• Solubility: Soluble to 1 mg/ml in water
• Storage: Desiccate at -20C
• IUPAC Name: (4S)-4-amino-5-[[(2S,3R)-1-[(2S)-2-[[(2S)-1-[[(4R,7S,10S,13S,16R,19R)-10-(4-aminobutyl)-16-benzyl-4-[[(1S)-1-carboxy-2-methylpropyl]carbamoyl]-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-3-carboxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
• InChI: InChI=1S/C64H85N13O18S2/c1-33(2)52(64(94)95)75-61(91)48-32-97-96-31-47(73-59(89)46(29-51(82)83)72-62(92)49-17-11-25-77(49)63(93)53(34(3)78)76-54(84)40(66)22-23-50(80)81)60(90)70-43(26-35-12-5-4-6-13-35)56(86)71-45(28-37-30-67-41-15-8-7-14-39(37)41)58(88)68-42(16-9-10-24-65)55(85)69-44(57(87)74-48)27-36-18-20-38(79)21-19-36/h4-8,12-15,18-21,30,33-34,40,42-49,52-53,67,78-79H,9-11,16-17,22-29,31-32,65-66H2,1-3H3,(H,68,88)(H,69,85)(H,70,90)(H,71,86)(H,72,92)(H,73,89)(H,74,87)(H,75,91)(H,76,84)(H,80,81)(H,82,83)(H,94,95)/t34-,40+,42+,43-,44+,45+,46+,47+,48+,49+,52+,53+/m1/s1
• InChIKey: HFNHAPQMXICKCF-WCNHMZSTSA-N
• SMILES: CC(C)C(C(=O)O)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)NC(=O)C(CC(=O)O)NC(=O)C6CCCN6C(=O)C(C(C)O)NC(=O)C(CCC(=O)O)N

Urotensin II (CAS 251293-28-4), a potent endogenous peptide agonist for the urotensin-II receptor (EC50 = 0.1 nM), displays arterio-selective vasoconstriction and vasodilatation in mammals in vitro and in vivo, effects which vary between species. It also has been shown to mediate bronchoconstriction.

Reference

1.Li, Ying-ying, et al. "The effects of urotensin II on migration and invasion are mediated by NADPH oxidase-derived reactive oxygen species through the c-Jun N-terminal kinase pathway in human hepatoma cells." Peptides 88 (2017): 106-114.
2.Pandey, Anubhuti, et al. "Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity." Current computer-aided drug design 11.4 (2015): 361-373.
3.Haensele, Elke, et al. "Conformation and dynamics of human urotensin II and urotensin related peptide in aqueous solution." Journal of chemical information and modeling 57.2 (2017): 298-310.